Delivery Order SPE2DB22D1017-SPE2DB25FF8UP

Award Date 3/27/25
Potential Completion Date 3/28/25
Potential Value $2.6K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,778.86 Firm Fixed Price contract is for the supply of 4,567,152,479 units of Tamsulosin HCL 0.4 mg capsules. The contract has a completion date of February 5, 2025 and was awarded on February 4, 2025. This order is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Tamsulosin HCL 0.4 mg capsules, with a ceiling value of $2,792.32 and a period of performance through May 5, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with DLA Troop Support Medical, valued at $999,999,999.00, which...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of Tamsulosin HCl 0.4 mg capsules. The contract has a ceiling value of $1,009.70 and a completion date of April 14, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The IDC covers a...
This is a Delivery Order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,715.49 firm fixed-price contract is for the delivery of 4,564,465,528 units of Tamsulosin HCl 0.4 mg capsules. The award is not designated as a set-aside contract. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical division, which serves as a primary vehicle for...
This is a Delivery Order contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) for the supply of 4,567,421,976 units of Tamsulosin HCL 0.4 mg capsules. The contract has a Firm Fixed Price pricing type and a ceiling value of $1,480.20. It does not have a set-aside designation. The contract is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at...
This is a Delivery Order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $9,394.02, is for the supply of Tamsulosin HCL 0.4 mg capsules in 1,000-count quantities. The contract has a period of performance through February 5, 2025 and utilizes a Firm Fixed Price pricing type. This Delivery Order contract is associated with a larger Indefinite Delivery Contract...
This is a $1,243.12 firm-fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of 4,567,903,368 capsules of the generic drug Tamsulosin HCL 0.4 mg. The delivery order has an ultimate completion date of April 15, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $8,859.17, is for the delivery of 1,000 units of Tamsulosin HCL 0.4 mg capsules. This award is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The IDC covers a...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,092.74, is for the delivery of 1,000 units of Tamsulosin HCL 0.4 mg capsules. The contract has a firm fixed price pricing type and an ultimate completion date of January 21, 2025. This contract is a task order under a larger Indefinite Delivery Contract (IDC) held by...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,990.26, is for the delivery of 4,567,985,363 units of Tamsulosin HCl 0.4 mg capsules. The contract is a firm fixed-price delivery order, with an ultimate completion date of April 22, 2025. AmerisourceBergen Drug Corp is the prime contractor, and there is no set-aside designation, indicating...
  • SPE2DB22D1017
    Indefinite Delivery Contract
  • SPE2DB22D1017-SPE2DB25FF8UP
    Delivery Order

This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the procurement of 4,567,721,093 units of Tamsulosin HCL 0.4 mg capsules, with a ceiling value of $2,585.21. This delivery order is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract award does not have a set-aside designation, indicating open competition.

Generated 6/26/25, 9:59 AM